Oral Answers to Questions

Tulip Siddiq Excerpts

Wednesday 21st February 2018 Commons Chamber

[The Prime Minister]

I am happy to agree with my hon. Friend on that point. I was in opposition when the Equality Act 2010 went through Parliament, and we supported that Act. It is there to ensure—exactly as he says—that people are treated equally.

[Tulip Siddiq (Hampstead and Kilburn) (Lab)]

Q10. The Government’s decision to leave Euratom and withdraw from the customs union could limit our access to vital cancer treatments. The chief executive officer of the Nuclear Industry Association—[Interruption.]

[Mr Speaker]

Order. Let us just be absolutely clear about this. This question, like every question, will be heard. The hon. Lady will not be shouted down and that is the end of the matter, so if some foolish person is seeking to do so, examine your behaviour and stop it.

[Tulip Siddiq]

Thank you, Mr Speaker.

The CEO of the Nuclear Industry Association points out that if medical isotopes that are used to treat cancer are delayed in reaching the UK, they could be deemed useless on arrival because of their short half-life. Will the Prime Minister explain how she plans to prevent delays to cancer treatment that would be caused by her pursuit of a hard Brexit?

[The Prime Minister]

The hon. Lady is wrong on two counts. First, we are pursuing a Brexit that will enable us to have an economic partnership that sees freedom of trade across the borders with the European Union. But it is also the case, as we have made clear previously, that the availability of medical radioisotopes will not be impacted by the UK’s exit from Euratom. The import or export of these radioisotopes is not subject to any Euratom licensing requirements, so our ability to import medical isotopes from Europe and the rest of the world will not be affected by our withdrawal from Euratom.